Clerkenwell Health

Clerkenwell Health is a UK-based clinical research organization specializing in psychedelic-assisted therapy trials, providing full-service CRO capabilities to sponsors developing treatments in this emerging field. The company manages the full spectrum of clinical trial operations, from site setup and patient recruitment to therapy delivery and regulatory compliance, with a focus on the unique demands of psychedelic medicine research. Operating dedicated trial sites across the United Kingdom, Clerkenwell Health combines purpose-built clinical infrastructure with specialist expertise in the therapeutic protocols required for psychedelic-assisted interventions. Their model is designed to accelerate the path from early-stage research to viable treatment options for conditions such as depression, PTSD, and addiction.

Clerkenwell Health has secured $8 million in Series A funding, reflecting growing investor confidence in both the company's operational model and the broader psychedelic medicine sector. The company has positioned itself as a specialist partner for pharmaceutical and biotech sponsors who require experienced infrastructure to navigate the regulatory and logistical complexities unique to psychedelic trials. By concentrating its capabilities within the UK, Clerkenwell Health is helping to establish Britain as a credible hub for psychedelic medicine research at a time when regulatory frameworks are beginning to evolve in this space. Their dedicated site network provides sponsors with a streamlined route to conducting high-quality studies without the burden of building proprietary research infrastructure.

Clerkenwell Health represents an important development for the neurotechnology and mental health sectors by providing the clinical scaffolding necessary to translate promising psychedelic research into validated, scalable therapies. As conventional psychiatric treatments continue to show limitations for conditions like treatment-resistant depression, the demand for novel neurologically targeted interventions is intensifying, and companies like Clerkenwell Health are critical enablers of that pipeline. Their work bridges the gap between scientific discovery and clinical application, helping to generate the rigorous evidence base that regulators, payers, and healthcare systems will require before psychedelic therapies can achieve mainstream adoption. In doing so, they are helping to shape a new frontier in neuroscience-driven mental health treatment.